Faruqi & Faruqi, LLP announced on April 4 that it is reminding investors in Aquestive Therapeutics, Inc. about the upcoming May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against the company.
The law firm said this notice is important for individuals who purchased or acquired Aquestive securities between June 16, 2025 and January 8, 2026 and may have suffered losses during that period. Investors are encouraged to contact James (Josh) Wilson, a partner at Faruqi & Faruqi, directly to discuss their legal rights.
“If you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310),” Wilson said in the announcement.
PR Newswire operates in more than 170 countries and provides support in over forty languages according to the official website official website. The organization aims to deliver global reach for press release distribution through its network of newsrooms and influencers according to its official website.
Additionally, PR Newswire features expert editors with over a decade of experience who provide continuous support and search engine optimization guidance as stated on its official site. The service collaborates with more than half a million media outlets and influencers worldwide according to information from its official website.
PR Newswire also offers services such as press release distribution tools enhanced by artificial intelligence as well as social sharing features as outlined on its official website.
